Tango Therapeutics, Inc. (TNGX) Stock Price & How to Invest

Tango Therapeutics works on synthetic lethality: finding drugs that kill cancer cells carrying a specific missing gene while leaving normal cells intact. Its central target is MTAP deletion, a defect present in roughly 10% to 15% of all cancers and a larger share of pancreatic and lung tumors. The lead asset is vopimetostat (formerly TNG462), an MTAP-selective PRMT5 inhibitor taken once daily, and the second clinical asset is TNG456, a brain-penetrant PRMT5 inhibitor aimed at glioblastoma. Two earlier candidates, TNG908 and TNG961, were dropped as the company concentrated resources. A discovery collaboration with Gilead was truncated during 2025, which is why the income statement shows ~$62 million of collaboration revenue in 2025 and exactly zero in each of the last three reported quarters. Tango had 137 employees as of its most recent disclosure and is run by Malte Peters, who replaced founder Barbara Weber; Weber's role as Executive Chair ended in early August 2026.

The investment picture changed on June 8, 2026. Tango reported initial Phase 1/2 data for vopimetostat combined with Revolution Medicines' RAS(ON) inhibitors in previously treated MTAP-deleted, RAS-mutant pancreatic cancer: a 92% objective response rate with daraxonrasib (11 of 12 evaluable patients, 9 confirmed) and a 90% six-month progression-free rate, plus a 52% response rate in a larger 27-patient arm with zoldonrasib. Management said it intends to move the daraxonrasib combination into a randomized Phase 3 in front-line pancreatic cancer. The day after, the company priced a $600 million offering at $30.00 per share through J.P. Morgan and Leerink, taking shares outstanding to roughly 174 million from about 108 million at the end of 2024 and pushing stated runway into 2030; cash stood at about $1.01 billion at June 30, 2026 against about $32 million of debt.

Since then the stock has cooled. Second-quarter results on August 11 showed a net loss of about $55.3 million, or $0.37 per share, wider than the $0.32 consensus on higher spending, and the shares fell about 5%. Revolution Medicines received an FDA approval in pancreatic cancer in late August (a drug reported as Rasonque), and on October 16 Tango said it will present updated vopimetostat plus RAS(ON) combination data at ESMO 2026. What an investor is buying at ~$3.8 billion is that readout carried forward: a Phase 3 not yet started, in a subset of a tumor type where nearly everything has failed, priced as though it works.

The headline number rests on 12 evaluable patients, only 9 of whose responses were confirmed, in an uncontrolled dose-escalation arm; response rates in small early cohorts routinely compress when a randomized trial adds a control group and a broader population, and the ESMO update is the first public test of that. Three dose-limiting toxicities were reported in two patients at the higher dose level, so the eventual Phase 3 dose is not settled. Tango does not control daraxonrasib: the combination's commercial value depends on Revolution Medicines' drugs and regulatory strategy, and any setback there reprices Tango without Tango doing anything wrong. The PRMT5 and MTAP field is crowded with far better-capitalized competitors including Amgen, Bristol Myers Squibb and AstraZeneca, any of which could reach the same patients first or with a cleaner profile. There is no product revenue to absorb a miss, spending is rising (the Q2 loss missed estimates), share count has risen from ~108 million at the end of 2024 to ~174 million, insiders sold shares in September and October 2026, and 2026 brought unusual turnover including a new CEO, a new CFO, two director resignations in May and the founder's departure as Executive Chair in August. The stock has already swung from a 52-week low near $6.69 to a high of $34.39 and back to the low $20s.

11 analysts publish price targets on TNGX, averaging $47.09 against a $22.08 price as of November 2026, or +113.3%. The published targets run from $24.00 to $69.00, a wide spread, and the ratings split 12 buy, 1 hold, 0 sell. Over the last six months there have been 8 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full TNGX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Tango Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The front-line pancreatic Phase 3. Everything in the current valuation routes through one trial that has not begun. The most optimistic published target, $69.00, assumes this works close to its best case.

The case against. The headline number rests on 12 evaluable patients, only 9 of whose responses were confirmed, in an uncontrolled dose-escalation arm; response rates in small early cohorts routinely compress when a randomized trial adds a control group and a broader population, and the ESMO update is the first public test of that. The most pessimistic target, $24.00, is roughly what TNGX is worth if this bites instead.

Read the full bull and bear case on TNGX, including what would have to change to break either one. Walnut is not an investment adviser.

No. Tango Therapeutics, Inc. (TNGX) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Tango Therapeutics, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$54M, all Gilead collaboration recognition; $0 in each of the last three reported quarters
• Net loss (Q2 2026): ~$55.3M, or ~$0.37 per share vs ~$0.32 expected
• Net loss (TTM): ~$124M; EPS ~-$0.85
• Cash and debt: ~$1.01B cash at June 30, 2026; ~$32M debt
• Market cap: ~$3.8B at ~$22.74 per share; 52-week range ~$6.69 to ~$34.39
• Price / book: ~3.7x
• Dividend: None

No conventional multiple applies, because there is no recurring revenue and the ~$54 million trailing figure is the tail of a collaboration that has already ended. Stripping out roughly $1.0 billion of cash leaves an enterprise value near $2.8 billion, which is what the market is assigning to vopimetostat, TNG456 and the discovery platform combined, down from about $3.7 billion in August. Eleven analysts tracked by Yahoo Finance rate the shares a Strong Buy on average with a mean target near $45, about double the current price, which says more about how binary the Phase 3 is than about any earnings path.

Other names that sit close to TNGX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

There are three common ways to get TNGX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so TNGX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where TNGX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

TNGX carries a roughly $3.8 billion valuation (about $2.8 billion net of cash) on a Phase 3 trial that has not started yet, built on a few dozen evaluable patients, with enough cash to run the trial and no revenue to cushion a miss. The stock has given back part of its summer gain since a wider-than-expected Q2 loss in August, and the next movers are the ESMO update and the Phase 3 design.

Whether TNGX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is TNGX a buy or a sell?, and where the stock could go from here in the TNGX stock forecast.

For income investors, whether TNGX pays a dividend and how the payout looks is covered in does TNGX pay a dividend? And to weigh TNGX against a peer, read the full side-by-side comparisons: TNGX vs AMGN and TNGX vs AMG.